Vitro BiopharmaVTRO Days Payable is 51.69 as of Oct. 2022, which is 94% below its 10-year median of 888.17. The stock has 6 warning signs investors should review.
The historical rank and industry rank for Vitro Biopharma's Days Payable or its related term are showing as below:
VTRO'
s Days Payable Range Over the Past 10 Years
Min: 57.19 Med: 888.17 Max: 5414.17
Current: 206.75
During the past 13 years, Vitro Biopharma's highest Days Payable was 5414.17. The lowest was 57.19. And the median was 888.17.
VTRO's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 113.56
vs VTRO: 206.75
Vitro Biopharma's Days Payable
declined
from Oct. 2014 (150.76) to Oct. 2022 (51.69).
It may suggest that Vitro Biopharmaaccelerated paying its suppliers.
Vitro Biopharma Days Payable Related Terms
Vitro Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Vitro Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vitro Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitro Biopharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Vitro Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vitro Biopharma's Days Payable for the fiscal year that ended in Oct. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitro Biopharma (VTRO) has a Days Payable of 51.69 as of Oct. 2022. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vitro Biopharma and its competitors. This is 94% below median its historical median of 888.17. Over the past decade, Vitro Biopharma's Days Payable has ranged from 57.19 to 5,414.17.
Is Vitro Biopharma's Days Payable too high?
Vitro Biopharma's current Days Payable of 51.69 is 94% below median its 10-year median of 888.17. Over the past 10 years, this metric has ranged from a low of 57.19 to a high of 5,414.17. The Biotechnology industry median Days Payable is 113.56. Vitro Biopharma's value of 51.69 is 54.5% below this industry median.
How does Vitro Biopharma's Days Payable compare to ?
Vitro Biopharma's Days Payable of 51.69 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.56. Vitro Biopharma's value of 51.69 is 54.5% below this benchmark. Historically, Vitro Biopharma's own Days Payable has ranged from 57.19 to 5,414.17 over the past decade. While the company's 10-year median is 888.17 vs. the industry median of 113.56, Vitro Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitro Biopharma's current Days Payable of 51.69 is 54.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vitro Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitro Biopharma's current Days Payable is 51.69, which is 94% below median its own 10-year median of 888.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Days Payable of 51.69. The current Days Payable is 51.69, which is 94% below median its 10-year median of 888.17 and 54.5% below the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Days Payable is 51.69 as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTRO has been successfully added to your 